Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 15Phase 1/2 14Phase EARLY_PHASE1 2Phase NA 1Phase 3 1Phase 2/3 1

Status

Completed 11Terminated 6Withdrawn 4Unknown 3Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 590Neoplasms 499Prostatic Neoplasms 316Lung Neoplasms 239Colorectal Neoplasms 201Motor Activity 134Carcinoma, Non-Small-Cell Lung 116Uterine Cervical Neoplasms 114Pancreatic Neoplasms 109Brain Neoplasms 109Head and Neck Neoplasms 104Stomach Neoplasms 100Rectal Neoplasms 98Carcinoma, Hepatocellular 97Ovarian Neoplasms 86Colonic Neoplasms 86Neoplasm Metastasis 68Esophageal Neoplasms 67Multiple Myeloma 65Hematologic Neoplasms 62Urinary Bladder Neoplasms 60Melanoma 59Sarcoma 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 58Glioblastoma 58Endometrial Neoplasms 57Glioma 53Anxiety Disorders 51Lymphoma 50Gastrointestinal Neoplasms 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Clear all
NCT05626400 2022-11-25

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡